Dataset Information

Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?

ABSTRACT: Methicillin-resistant Staphylococcus aureus (MRSA) has recently caused epidemic outbreaks of community-associated (CA) skin infections. The infecting strains frequently contain the genes encoding the staphylococcal toxin, Panton-Valentine leukocidin (PVL). On that ground, the use of PVL-based vaccines has been proposed for the treatment of CA-MRSA infections, despite experimental and epidemiological evidence that does not support a major role of the PVL toxin in CA-MRSA skin disease. Hermos et al. show that antibodies to PVL do not protect from CA-MRSA skin infections in children, strongly suggesting that PVL-based immunization is of little benefit for this most frequent disease caused by CA-MRSA.

SUBMITTER: Otto M

PROVIDER: S-EPMC3106302 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?

Otto Michael M

Expert review of anti-infective therapy 20110401 4

Methicillin-resistant Staphylococcus aureus (MRSA) has recently caused epidemic outbreaks of community-associated (CA) skin infections. The infecting strains frequently contain the genes encoding the staphylococcal toxin, Panton-Valentine leukocidin (PVL). On that ground, the use of PVL-based vaccines has been proposed for the treatment of CA-MRSA infections, despite experimental and epidemiological evidence that does not support a major role of the PVL toxin in CA-MRSA skin disease. Hermos et a ...[more]

PMID: 21504395

Similar Datasets

Project description:IntroductionSkin and soft tissue infections (SSTI) caused by Panton-Valentine leukocidin (PVL)-producing strains of Staphylococcus aureus (PVL-SA) are associated with recurrent skin abscesses. Secondary prevention, in conjunction with primary treatment of the infection, focuses on topical decolonization. Topical decolonization is a standard procedure in cases of recurrent PVL-SA skin infections and is recommended in international guidelines. However, this outpatient treatment is often not fully reimbursed by health insurance providers, which may interfere with successful PVL-SA decolonization.AimOur goal was to estimate the cost effectiveness of outpatient decolonization of patients with recurrent PVL-SA skin infections. We calculated the average cost of treatment for PVL-SA per outpatient decolonization procedure as well as per in-hospital stay.MethodsThe study was conducted between 2014 and 2018 at a German tertiary care university hospital. The cohort analyzed was obtained from the hospital's microbiology laboratory database. Data on medical costs, DRG-based diagnoses, and ICD-10 patient data was obtained from the hospital's financial controlling department. We calculated the average cost of treatment for patients admitted for treatment of PVL-SA induced skin infections. The cost of outpatient treatment is based on the German regulations of drug prices for prescription drugs.ResultsWe analyzed a total of n = 466 swabs from n = 411 patients with recurrent skin infections suspected of carrying PVL-SA. PVL-SA was detected in 61.3% of all patients included in the study. Of those isolates, 80.6% were methicillin-susceptible, 19.4% methicillin-resistant. 89.8% of all patients were treated as outpatients. In 73.0% of inpatients colonized with PVL-SA the main diagnosis was SSTI. The median length of stay was 5.5 days for inpatients colonized with PVL-SA whose main diagnosis SSTI; the average cost was €2,283. The estimated costs per decolonization procedure in outpatients ranged from €50-€110, depending on the products used.ConclusionOur data shows that outpatient decolonization offers a highly cost-effective secondary prevention strategy, which may prevent costly inpatient treatments. Therefore, health insurance companies should consider providing coverage of outpatient treatment of recurrent PVL-SA skin and soft tissue infections.

Dataset Information

Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?

Publications

Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets